130 related articles for article (PubMed ID: 1477079)
1. Repetitive weekly cycles of 4-day continuous infusion of recombinant interleukin-2: a phase I study.
Punt KC; Jansen RL; De Mulder PH; Batchelor D; Galazka A; Bolhuis RL; Stoter G
J Immunother (1991); 1992 Nov; 12(4):277-84. PubMed ID: 1477079
[TBL] [Abstract][Full Text] [Related]
2. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
3. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; AramendÃa JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
4. A phase IA/IB trial of anti-CD3 murine monoclonal antibody plus low-dose continuous-infusion interleukin-2 in advanced cancer patients.
Sosman JA; Kefer C; Fisher RI; Jacobs CD; Pumfery P; Ellis TM
J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):171-80. PubMed ID: 7613643
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients.
Sosman JA; Fisher SG; Kefer C; Fisher RI; Ellis TM
Ann Oncol; 1994 May; 5(5):447-52. PubMed ID: 7521206
[TBL] [Abstract][Full Text] [Related]
7. Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.
Goldstein D; Sosman JA; Hank JA; Weil-Hillman G; Moore KH; Borchert A; Bechhofer R; Storer B; Kohler PC; Levitt D
Cancer Res; 1989 Dec; 49(23):6832-9. PubMed ID: 2819723
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
9. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
Goey SH; Eggermont AM; Punt CJ; Slingerland R; Gratama JW; Oosterom R; Oskam R; Bolhuis RL; Stoter G
Br J Cancer; 1995 Nov; 72(5):1283-8. PubMed ID: 7577483
[TBL] [Abstract][Full Text] [Related]
10. Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.
Sano T; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Sakurai M; Takahashi H; Nakano H; Nakagawa K
Jpn J Cancer Res; 1988 Jan; 79(1):131-43. PubMed ID: 3128501
[TBL] [Abstract][Full Text] [Related]
11. A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.
Creekmore SP; Harris JE; Ellis TM; Braun DP; Cohen II; Bhoopalam N; Jassak PF; Cahill MA; Canzoneri CL; Fisher RI
J Clin Oncol; 1989 Feb; 7(2):276-84. PubMed ID: 2783732
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.
Choi BS; Sondel PM; Hank JA; Schalch H; Gan J; King DM; Kendra K; Mahvi D; Lee LY; Kim K; Albertini MR
Cancer Immunol Immunother; 2006 Jul; 55(7):761-74. PubMed ID: 16187086
[TBL] [Abstract][Full Text] [Related]
13. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
[TBL] [Abstract][Full Text] [Related]
14. Biologic and clinical effects of continuous infusion interleukin-2 in patients with non-small cell lung cancer.
Ardizzoni A; Bonavia M; Viale M; Baldini E; Mereu C; Verna A; Ferrini S; Cinquegrana A; Molinari S; Mariani GL
Cancer; 1994 Mar; 73(5):1353-60. PubMed ID: 8111701
[TBL] [Abstract][Full Text] [Related]
15. Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.
Sosman JA; Hank JA; Moore KH; Borchert A; Schell K; Kohler PC; Goldstein D; Bechhofer R; Storer B; Albertini MR
Cancer Invest; 1991; 9(1):35-48. PubMed ID: 2012995
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.
Meropol NJ; Barresi GM; Fehniger TA; Hitt J; Franklin M; Caligiuri MA
Cancer Immunol Immunother; 1998 Aug; 46(6):318-26. PubMed ID: 9756416
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
18. Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients.
Weil-Hillman G; Hank JA; Rosenthal NS; Sondel PM
J Biol Response Mod; 1988 Oct; 7(5):424-37. PubMed ID: 3053997
[TBL] [Abstract][Full Text] [Related]
19. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity.
Bernstein ZP; Porter MM; Gould M; Lipman B; Bluman EM; Stewart CC; Hewitt RG; Fyfe G; Poiesz B; Caligiuri MA
Blood; 1995 Nov; 86(9):3287-94. PubMed ID: 7579429
[TBL] [Abstract][Full Text] [Related]
20. Phase I study combining tumor necrosis factor with interferon-alpha and interleukin-2.
Eskander ED; Harvey HA; Givant E; Lipton A
Am J Clin Oncol; 1997 Oct; 20(5):511-4. PubMed ID: 9345339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
